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Hepcidin is a liver-synthesized hormone that plays a central role in the regulation of systemic 
iron homeostasis. To produce a new tool for its functional properties the cDNA coding for 
camel hepcidin-25 was cloned at the 5’end of human FTH sequence into the pASK-
IBA43plus vector for expression in E. coli. The recombinant fusion hepcidin-ferritin-H 
subunit was isolated as an insoluble iron-containing protein. When alone it did not refold in a 
24-mer ferritin molecule, but it did when renatured together with H- or L-ferritin chains. We 
obtained stable ferritin shells exposing about 4 hepcidin peptides per 24-mer shell. The 
molecules were then reduced and re-oxidized in a controlled manner to allow the formation of 
the proper hepcidin disulfide bridges. The functionality of the exposed hepcidin was 
confirmed by its ability to specifically bind the mouse macrophage cell line J774 that express 
ferroportin and to promote ferroportin degradation. This chimeric protein may be useful for 







There has been significant progress in identifying the molecules controlling iron homeostasis 2	
and their mode of action (Recalcati et al., 2010; Pantopoulos et al., 2012). Hepcidin is the key 3	
iron regulatory hormone (Ganz, 2003). It is a 25 amino acid peptide belonging to the β -4	
defensin family, isolated for the first time from plasma and human urine (Krause et al., 2000; 5	
Park et al., 2001), and consists of a cysteine-rich cationic peptide engaged with four disulfide 6	
bridges which plays a major role in innate immunity and iron homeostasis (Falzacappa and 7	
Muckenthaler, 2005; Houamel et al., 2016). It is induced by iron abundance and inflammation 8	
and is suppressed by iron deficiency and hypoxia. Recently it has been reported that 9	
circulating hepcidin-25 is reduced by endogenous estrogen in humans (Lehtihet et al., 2016). 10	
Hepcidin binds and inhibits ferroportin1, the only cellular iron exporter (Ramey et al., 2010) 11	
and thus, high hepcidin reduces while low hepcidin increases systemic iron availability 12	
(Nemeth and Ganz, 2006). Furthermore, modulation of this peptide can offer promising 13	
clinical applications to treat iron deregulation (Blanchette et al., 2016). Hepcidin acts via its 14	
N-terminal domain of 7–9 amino acids, including a thiol cysteine, that is the minimal 15	
structure retaining hepcidin activity (Preza et al., 2011). The 3D structure of human hepcidin 16	
is known (Jordan et al., 2009). Recombinant human and mouse hepcidins were expressed in 17	
E. coli in fusion with a thioredoxin and treated by two sequential proteolytic enzymes to 18	
obtain functional hepcidin, in low yield < 10% (Gagliardo et al., 2008). A similar procedure 19	
was used to clone and express camel hepcidin, which showed to be functionally equivalent to 20	
the human one in binding and inhibiting ferroportin, using mouse monocyte-macrophage cell 21	
line J774 treated with Fe-nitrilotriacetate (Boumaiza et al., 2015). Here we planned to fuse 22	
camel hepcidin with human ferritin H-chain to obtain a chimeric camel hepcidin-human 23	
ferritin H-chain subunit (HepcH). 24	
Ferritin is a spherical protein complex formed by 24 subunits of H- and L-chains which stores 25	
up to 4,000 iron atoms as an oxidized mineral core (Arosio et al., 2009). It is probably the 26	
most used protein in bionanotechnology. This is due to its well-known structural features, 27	
high stability, capability to mineralize metals in its cavity, self-assembly and possibility to 28	
redesign its interior and exterior by protein engineering (Martsev et al., 1998; Kanekiyo et al., 29	
2013; Jutz et al., 2015). It has been used to encapsulate molecules, for the synthesis of 30	
inorganic cores, for functional nanostructured composite material, for magnetic nanoparticles 31	
with MRI applications and for carrying various epitopes (Cai et al., 2015). Most studies used 32	
the human H or L ferritin chains, which are able to self-assemble in different proportions to 33	
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produce a variety of heteropolymers (Santambrogio et al., 1993; Rucker et al., 1997). This 34	
allows the possibility to decorate ferritin surface with multiple functionalities through genetic 35	
and chemical modification to achieve desired properties for therapeutic and/or diagnostic 36	
purposes (Jeon et al., 2013). In particular, it can be used as peptide carrier that can target 37	
specific receptors. 38	
In the present study, we describe an approach to produce and purify a chimeric camel 39	
hepcidin-human ferritin H-chain fusion protein (HepcH) that can be renatured onto a stable 40	
24-mer ferritin shell when co-assembled together with human H- and L-chains. In addition, 41	
we demonstrate that the resulting assembled hybrid HepcH-FTH or -FTL is able to target the 42	
iron exporter ferroportin inducing its cellular internalization. 43	
 44	
Materials and Methods 45	
Plasmid construction 46	
The construct that overproduces HepcH monomer in E.coli was done in the pASK-IBA43plus 47	
vector (IBA, BioTAGnology). The first step was the insertion of the full human FTH cDNA, 48	
amplified by PCR using the primers NheI hFTH F / BamHI hFTH R (Table S1), in the NheI 49	
and BamHI sites. The second step was the insertion of camel hepcidin coding region cDNA, 50	
amplified by PCR using the primers NheI H25 F / NheI H25 R (Table S1), in the NheI site at 51	
the 5’end of huFTH sequence. The construct was verified by DNA sequencing, using the 52	
primers pASK F / pASK R (Table S1), which confirmed that the sequence of camel hepcidin-53	
human ferritin H-chain was correct.  54	
Expression and solubilization of HepcH monomer 55	
Human ferritin H-chain fused directly downstream the mature camel hepcidin was cloned into 56	
the pASK-43 plus vector and expressed using BL21 (DE3) pLys E. coli strain. Growth of the 57	
transformed E. coli was done in 1 L LB medium (10 g Tryptone, 5 g Yeast extract, 5 g NaCl), 58	
with 100 µg/mL ampicillin, at 37°C, for 1-2 h until the culture reached an optical density 59	
(OD600) of 0.5.  Then the expression was induced by the addition of anhydrotetracycline with 60	
a final concentration of 200 µg/L, for 4 h. Cells were harvested by centrifugation at 7,000 61	
RPM for 10 min. The pellet was washed twice in Tris-HCl 20 mM pH 7.4 and sonicated for 62	
cytoplasmic protein extraction. The sonicate pellet was then collected at 12,000 RPM and 63	
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washed twice in Tris 20 mM, 2 M Urea, 0.1% Triton X100, pH 7.4. The insoluble HepcH 64	
monomer was solubilized with a weight to volume ratio of 1:1 in 6 M Guanidine 65	
hydrochloride (GdnHCl) pH 4.7 and incubated with stirring for 18 h at 4°C. The suspension 66	
was sonicated to homogenize the solution. 67	
HepcH construct is expressed in association with iron  68	
Iron content in HepcH construct was determined by ferrozine assay. Briefly, the solubilized 69	
HepcH construct (4.5 µM) was incubated with 1 mM TCEP (Tris(2-carboxyethyl)phosphine 70	
hydrochloride, Sigma) in the presence of an excess of ferrozine (3-(2-Pyridyl)-5,6-diphenyl-71	
1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate, Sigma) in 50 mM Tris-HCl 72	
buffer pH 7.0. The rate of Fe(II) release was monitored by reading at 562 nm the formation of 73	
the ([FeII(fz)3]) complex (ɛ562= 28,000 M-1 cm-1). In parallel, a control containing HepcH 74	
construct (4.5 µM) and ferrozine, in absence of TCEP, was also monitored at 562 nm. 75	
Absorbance measurements were recorded using a Cary 50 Bio UV-vis spectrophotometer. 76	
Thiol quantification 77	
Thiol quantification of HepcH monomer was done using Ellman’s method (Ellman, 1959). 78	
Briefly, the solubilized HepcH monomer (0.12 mg/mL, 5 µM) was first fully reduced by 79	
incubation with a molar excess of TCEP (tris(2-carboxyethyl)phosphine, Sigma) at 4ºC. After 80	
1 h of incubation, the pH was lowered to 3.5-4 by drop-wise addition of 0.1 N HCl to inhibit 81	
disulfide bond formation, and the excess of unreacted TCEP was removed by successive 82	
dialysis steps at pH 4 using a 12 kDa dialysis membrane (Sigma). Free sulfhydryl 83	
quantification was then performed by incubation for 1 hour at room temperature with an 84	
excess of DTNB (5,5’-Dithio-bis-(2-nitrobenzoic acid), Sigma) at a final concentration of 500 85	
µM in a reaction buffer containing 0.1 M sodium phosphate, 1 mM EDTA at pH 8. The total 86	
concentration of free thiol groups was measured spectrophotometrically at 412 nm using a 87	
value of 14,150 M-1 cm-1 for the molar extinction coefficient of TNB2-. For free sulfhydryl-88	
group detection in the final renatured HepcH-FTH and HepcH–FTL samples, we used the 89	
protocol described above without the reductive step with TCEP.  90	
Assembly of HepcH-FT heteropolymers  91	
Assembly of HepcH in an heteropolymeric molecule was performed by adding denatured 92	
FTH or FTL before renaturation, followed by 10-fold dilution in buffer. Prior to the refolding, 93	
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the HepcH monomer was made iron-free following the protocol described by Levi et al. with 94	
slight modifications (Levi et al., 1988). Briefly, solubilized HepcH monomer in 6 M GdnHCl 95	
was incubated with 1% thioglycolic acid, pH 5.5, and 2,2-bipyridyle followed by 48 h 96	
extensive dialysis against 6 M GdnHCl, pH 7.0. Once iron-free, the resulting clear colorless 97	
and unfolded HepcH sample was incubated with different ratios of FTH or FTL denatured in 98	
6 M or 8 M GdnHCl respectively, at pH 3.5, using different HepcH/FT molar ratios (5:1; 1:1; 99	
1:2; 1:5; 1:11). The mixture was then refolded by at least 10-fold dilution into 0.1 M Tris-HCl 100	
buffer pH 7.4, 2 mM TCEP, and then incubated at 4°C for 1-2 days. The resulting solution 101	
was then clarified by centrifugation at 4,000 RPM for 15 min, concentrated 10-fold using a 102	
100 kDa molecular weight cut-off centrifugal filter (Millipore, Billerica, Massachusetts) and 103	
analyzed in 7% non-denaturing PAGE. Cysteine oxidation for the final refolded HepcH-FTH 104	
and HepcH-FTL heteropolymers renatured in the proportions 1:2; 1:5 and 1:11, was carried 105	
out using the glutathione redox system (GSH/GSSG) as described by Jordan et al. (Jordan et 106	
al., 2009). Briefly, the refolded hybrid ferritin samples containing HepcH construct were 107	
dialyzed for 48 h at 4ºC using a 12 kDa dialysis membrane (Sigma) against a buffer 108	
containing 0.1 M Tris pH 8 and 0.4 mM GSH/ 0.4 mM GSSG in order to slowly oxidize 109	
cysteine thiols in parallel with gradual removal of the TCEP, enhancing thus the 110	
intramolecular S-S formation. Then the sample was thoroughly dialyzed at room temperature 111	
against 20 mM Tris-HCl pH 7.4 to remove the GSG/GSSG redox system and the resulting 112	
oxidized HepcH-FTH and -FTL were run on a native 7% PAGE. Sample concentration was 113	
measured with Bradford assay (Biorad) using BSA as a control. 114	
Western blot analysis 115	
Samples of 30 µg of protein were loaded on 12% SDS-PAGE or 7% non-denaturing PAGE 116	
and then blotted onto Amersham Western blotting membrane (GE Healthcare, Life Sciences) 117	
with monoclonal anti-human FTH and FTL (Sigma Aldrich) and polyclonal anti-hepcidin 118	
(Rabbit anti-hepcidin-25, Abcam) antibodies for SDS-PAGE. For non-denaturating PAGE, 119	
monoclonal antibodies rH02 and LF03, prepared against human ferritin H- and L-chains 120	
respectively, were used as previously described (Luzzago et al., 1986; Cozzi et al., 1989). 121	
Briefly, the membrane was blocked with 2% defatted milk in TBS-T for 30 min at 37°C under 122	
agitation and then incubated with anti-human FTH or FTL (1:1,000) and anti-hepcidin 123	
(1:1,000) primary antibodies during 1-2 h at 37°C or overnight at 4°C. After washing 3 times 124	
with TBS-T, the membrane was incubated for 1 h at 37°C with the secondary anti-mouse 125	
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(1:20,000) and then with anti-rabbit (1:15,000) antibodies conjugated with peroxidase (anti-126	
mouse immunoglobulin G, Dako or anti-rabbit immunoglobulin G, BioFX Laboratories). 127	
After washing 3 times at room temperature the signal was revealed by enhanced 128	
chemiluminescence (ECL) kit (GE, Healthcare) and recorded with KODAK Image Station 129	
440CF (Kodak).  130	
Matrix-Assisted Laser Desorption/Ionization (MALDI) Time-of-Flight (TOF)/TOF Mass 131	
Spectrometry (MS) [MALDI-TOF/TOF–MS] analysis 132	
MALDI-TOF/TOF–MS analysis was performed on AB Sciex 5800 MALDI-TOF/TOF–MS 133	
as described by Gianoncelli and coworkers (Gianoncelli et al., 2015).  134	
Cellular studies 135	
Mouse monocyte-macrophage cell line J774 (Lombardy and Emilia Romagna Experimental 136	
Zootechnic Institute) was cultured as previously described (Delaby et al., 2005). Briefly, cells 137	
were grown in DMEM (PAA Laboratories GmbH), 10% endotoxin-free fetal bovine serum 138	
(Euroclone), 0.04 mg/mL gentamicin (Euroclone), 2 mM L-glutamine (PAA Laboratories 139	
GmbH), and maintained at 37°C in 5% CO2. Cells (200,000 cells/well) were seeded onto 12-140	
well plates, and after 24 h were grown for 12 h in presence of 100 µM ferric ammonium 141	
citrate (FAC) to induce ferroportin expression. The day after, cells were incubated with the 142	
hybrid ferritin heteropolymers containing different ratio of HepcH:FTH at a final 143	
concentrations of 0.2 µM (1:5) and 0.2 µM (1:11) and HepcH:FTL at a final concentrations of 144	
0.1 µM (1:5) and 0.2 µM (1:11). The controls were cells without FAC treatment and the 145	
native FTH and FTL homopolymers at the same concentrations. Experiments were done at 146	
37°C for 15, 30, 60 and 120 minutes. After this time, the supernatant was discarded and the 147	
cells washed with cold PBS and lysed using cold buffer (200 mM Tris-HCl at pH 8, 100 mM 148	
NaCl, 1 mM EDTA, 0.5% NP-40, 10% glycerol, 1 mM sodium fluoride, 1 mM sodium 149	
orthovanadate, Protease Inhibitor Cocktail; Roche). Protein content was determined by 150	
colorimetric BCA assay (bicinchoninic acid assay, Pierce) and 20 µg of total proteins were 151	
separated by native polyacrylamide gel electrophoresis and Western Blotting was performed 152	
using polyclonal anti-rabbit ferroportin, anti-human FTH (RH02) and FTL (LF03) antibodies 153	





Chimeric construct for HepcH expression  157	
The HepcH plasmid construct encoding the sequence of the mature camel hepcidin fused to 158	
that of the human H ferritin (huFTH) is shown in Fig. 1A. In the ferritin shell the N-terminus 159	
of the subunits is exposed, thus the fused hepcidin is expected to be accessible and available 160	
for ferroportin binding. The HepcH monomer of 213 amino acids (Fig. 1A and Table I) was 161	
efficiently expressed by the transformed E. coli and it had the expected molecular size of 24 162	
kDa on SDS-PAGE (Fig. 1B). In immunoblotting experiments, the HepcH monomer was 163	
recognized by antibodies specific for human FTH and for hepcidin-25, which also recognized 164	
the recombinant FTH and the commercial human Hepcidin-25, respectively (Fig. 1C). In 165	
MALDI-TOF mass spectrometry, HepcH monomer solubilized in 6 M GdnHCl pH 4.7, 166	
exhibited a peak at m/z 24339.55 corresponding to the theoretical average mass of 24410.50 167	
(Fig. 1D and Table I). The peak at m/z 48466.0313 corresponds to HepcH dimer (Fig. 1D). 168	
 The insoluble HepcH is expressed in association with iron 169	
The insoluble fractions of the homogenate of cell expressing HepcH subunit showed a distinct 170	
reddish color not present in those expressing huFTH (Fig. 2A). Treatments of the precipitates 171	
with 6 M urea at pH 4.5–5.0 solubilized the recombinant protein together with the color (Fig. 172	
2A). The UV/Vis absorption spectra of solubilized HepcH subunit showed a major peak at 173	
280 nm and a shoulder around 420 nm (Fig. 2B, black line) not present in ferritin H-chain 174	
(Fig. 2B, grey line) that decreased after reduction with 100 mM dithionite (Fig. 2B, dashed 175	
line). A similar behavior was described for a FTH-Hepcidin chimera expressed in E.coli in 176	
association with iron (Gerardi et al., 2005). The iron bound to HepcH was quantified amounts 177	
by chelation with ferrozine. The solubilized preparation was incubated with ferrozine and an 178	
agent (TCEP) to reduce iron, and the formation of the ([FeII(fz)3]) complex was followed by 179	
its absorbance at 562 nm. The colorimetric reaction started immediately after addition of 180	
TCEP and reached a plateau after 24 hours (Fig. 2C). In the absence of reducing agent, the 181	
color development was negligible (Fig. 2D) indicating that the bound iron is the Fe(III) form. 182	
We calculated a value of ~19 µM of iron in the complex, corresponding to about 4.1 Fe atoms 183	
per HepcH monomer, as isolated.  184	
Quantification of free sulfhydryl groups in the solubilized HepcH 185	
FTH has 3 Cys and hepcidin has 8, thus the detection of the free thiols was of interest. The 186	
purified HepcH peptide was subjected to Ellman's assay. The absorbance spectra of HepcH 187	
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incubated with 500 µM of DTNB before and after reduction of the thiols are shown in Fig. 188	
S1. We calculated ~38.7 µM of sulfhydryl groups in the HepcH sample after full reduction 189	
corresponding to about 7.7 free sulfhydryl per HepcH monomer (Fig. S1, bars). This indicates 190	
that all the thiols are not accessible under non-reducing conditions, and that after reduction 191	
about 8 out of 11 become accessible, confirming the presence of the hepcidin extension in the 192	
purified HepcH construct.  193	
Assembly, oxidation and characterization of HepcH-FTH and HepcH-FTL heteropolymers 194	
Initial experiments to renature HepcH by diluting the denatured peptide into the renaturing 195	
buffers as in (Santambrogio et al., 1993) were unsuccessful, indicating that the N-terminal 196	
hepcidin interferes with folding or assembly. Thus, we tried the co-renaturation together with 197	
H- or L-chains, on the basis of previous evidence that co-assembly facilitates the folding of 198	
altered ferritin chains (Levi et al., 1994). We set up a series of experiments in which the 199	
denatured and reduced HepcH was firstly mixed with denatured FTH or FTL at different 200	
ratios, and then refolded by 10-fold dilution in buffer to test the formation of stable ferritin 201	
shells. We obtained heteropolymeric ferritins composed of HepcH and FTH or FTL only 202	
when mixed in the proportions 1:11; 1:5 and in a less extent in 1:2. The assembled ferritin 203	
shells produced a single discrete band in 8% non-denaturing PAGE, the mobility of which 204	
decreased with the increase of HepcH, an indirect support that the hepcidin moiety is exposed 205	
and slows the mobility (Fig. 3A and 3B). When the refolding was done with higher 206	
proportions of HepcH:FT (1:1, 2:1 and 5:1), the product showed a large smear on PAGE 207	
indicating the formation of disordered and poorly structured molecules (Fig. 3A). 208	
Immunoblotting with anti-human FTH and anti-hepcidin antibodies, confirmed the presence 209	
of HepcH construct assembled in ferritin shells (Fig. 3C). A schematic representation of the 210	
renatured HepcH-FT hybrid heteropolymer is shown in the Fig. 3D. Renaturation of the 211	
hybrid ferritins was done under reducing conditions, and thus needed the re-oxidation of the 212	
hepcidin cysteines to form the four disulfide bridges present in hepcidin structure. For this 213	
reason, the hybrid ferritins were incubated with the glutathione redox system at pH 8 to 214	
promote formation of thiosulfate anions, which represent the reactive species during disulfide 215	
formation. The redox pair consisted of reduced and oxidized glutathione at concentrations of 216	
0.4 mM each, followed by extensive dialysis. The final oxidized heteropolymeric HepcH-217	
FTH and HepcH-FTL showed the typical ferritin monomer and oligomers ladder pattern in 218	
PAGE (Fig. 4A) and no free thiols could be detected by Ellman’s reaction testifying the full 219	
oxidation of the eight cysteine residues constituting the camel hepcidin (Fig. 4B, bars). 220	
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MALDI-TOF spectra of the final oxidized HepcH-FTH heteropolymer exhibited, average 221	
mass peaks at m/z 21,296.84 and at 24,338.90 (Fig. S2 A and Table I) which corresponds to 222	
the theoretical average mass [M+H]+ of 21,225.64 of FTH (183 amino acids), and of 223	
24,410.50 to HepcH (213 amino acids). The HepcH-FTL showed a peak at 20,055.41 and at 224	
24,230.14, the former corresponding to the 20,019.67 of FTL (175 amino acids) monomers 225	
(Fig. S2 and Table I). The differences between the theoretical and experimental masses is due 226	
to the instrument settings that for mid/high MW uses only one time of flight and has low 227	
resolution with deviations up to 100 Da. 228	
The HepcH-FTH heteropolymers bind macrophagic cells and cause ferroportin degradation  229	
The major hepcidin function is to bind ferroportin exposed to cellular plasma membrane an 230	
activity that we expected could be monitored by taking advantage of the ferritin bound to it. 231	
To verify this, we incubated the mouse macrophage J774 cell with 100 µM FAC to induce 232	
ferroportin expression, the cells were incubated with the heteropolymers using FTH and FTL 233	
homopolymers as controls. Immunoblotting with anti-ferritin antibodies showed that HepcH-234	
FTH and FTL were strongly retained by the cells after 2h of incubation using the molar ratio 235	
HepcH/FT of 1:5 (Fig. 5A and 5B). However, 15-30min of cell treatment was insufficient for 236	
the binding of this ferritins on the macrophage cell surface (data not shown). Moreover, the 237	
FTH and FTL homopolymers were retained only in trace amounts after 2h of incubation (Fig. 238	
5A and 5B). Interestingly, the intensity of the binding increased with the increase of the 239	
proportion of HepcH in the heteropolymers, both with FTH and FTL (Fig. 5A and 5B, ratio 240	
1:5 versus 1:11). This indicates that the binding can be safely attributed to the exposed 241	
hepcidin moiety that likely interacts with ferroportin. After binding, the hepcidin role is to 242	
induce ferroportin degradation, therefore to verify this we analyzed the ferroportin content of 243	
the treated cells by western blotting using anti-ferroportin antibodies. Figure 5C shows that 244	
the recombinant heteropolymer HepcH-FTH induced a degradation of ferroportin similar to 245	




The production of a functional hepcidin attached to a large multimeric protein like ferritin 250	
may be useful to follow hepcidin binding to ferroportin and analyze its functionality. In a 251	
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previous approach, we fused the hepcidin moiety at the C-terminus of ferritin, but the 252	
hepcidin was buried inside the cavity and thus not functional (Gerardi et al., 2005). Here we 253	
succeed to fuse at the N-terminus of the ferritin H-chain a camel hepcidin, which differs from 254	
the human one in only 2 residues and is similarly functional and more stable (Boumaiza et al., 255	
2014, 2015). This strategy was expected to display the N-terminal domain of hepcidin 256	
exposed and available to the interaction with ferroportin (Nemeth et al., 2005; Preza et al., 257	
2011). The HepcH construct was efficiently expressed in E. coli as insoluble reddish 258	
aggregate rich in iron. The approaches to renature the construct were unsuccessful, indicating 259	
that the hepcidin moiety interferes with the process of ferritin folding and assembly. This did 260	
not occur when hepcidin was fused at the C-terminus and formed soluble and stable ferritin 261	
shells (Gerardi et al., 2005). A common property of the two chimeric constructs is the binding 262	
of iron during expression in E. coli, which in the present study was calculated to be about 4 263	
iron atoms per hepcidin molecule. The spectroscopic characteristics of the HepcH construct as 264	
isolated were reminiscent to the ones of Fe/S clusters. Its UV/vis spectrum showed a broad 265	
shoulder at 420 nm, which was absent in the wild-type ferritin. This is very likely due to the 266	
Cys dense sequence of hepcidin that may form active iron binding sites under low potential 267	
conditions. In fact, we found that the thiols of these Cys were not available if not treated with 268	
reducing agents. The insolubility of the HepcH was initially attributed to the Cys-iron 269	
complexes, but also the approaches to renature it under reducing conditions failed, indicating 270	
that the hepcidin moiety interferes with the folding/assembly. To solve this problem, we took 271	
advantage of the capacity of ferritin subunits to co/assemble together and facilitate their 272	
folding. For example, an insoluble L-chain with ferroxidase activity was induced to fold and 273	
assemble together with wild type L-chain (Levi et al., 1994). This approach worked also in 274	
this situation and we obtained heteropolymers of HepcH with both the H- and L-chains. We 275	
tried different HepcH:FTH and HepcH:FTL molar ratios, and we obtained a maximum 276	
number of about 4 HepcH subunits per shell (ratio 1:5). When HepcH was in excess, the 277	
renaturation was not successful. The ferritins so obtained retained all the characteristics of 278	
hybrid molecules, including the electrophoretic mobility and the recognition by antibodies for 279	
the two moieties, ferritin and hepcidin. Of interest is that disulfide bridges are not involved in 280	
wild-type ferritin stability, and thus the hybrid ferritin shells could be treated with glutathione 281	
redox system to allow the proper formation of the hepcidin disulfides bonds. This was 282	
apparently successful, since after the treatments no thiol group was accessible to Ellman’s 283	
reagent, and, more important, the heteropolymers was able to bind J774 cells exposing 284	
ferroportin. The specificity of the binding to the cells was indicated by the evidence that it 285	
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occurred only with the HepcH-containing molecules and that its strength was related to the 286	
HepcH content. A minor binding was found with FTH homopolymers, probably due to the 287	
expression of the H-ferritin receptor TIM-2 in these cells (Han et al., 2011), while the binding 288	
of the FTL homopolymer was negligible. Hepcidin exerts it function by binding and then 289	
inducing ferroportin degradation, and in fact we observed that after 2 h incubation with 290	
HepcH-FTH the level of ferroportin in the J774 cells decreased, as it occurred in the cells 291	
treated with the synthetic hepcidin, while the incubation with FTH had no evident effect. This 292	
indicates that heteropolymer is biologically functional.  293	
In conclusion, present data show a genetic approach to produce hepcidin displayed on ferritin 294	
surface. Fusion hepcidin-ferritin H subunit assembled together with H- or L-chains at a ratio 295	
of 1:5, produced a stable and functional 24-mer ferritin exposing about 4 hepcidin per shell. 296	
The evidence that this molecule specifically binds cells that express high levels of ferroportin 297	
indicates that it might be an interesting tool to study more in detail the mechanism of 298	
interaction of hepcidin and ferroportin and how the complex is degraded. It might also be 299	
used as an alternative approach for the development of new concepts and prodrugs of 300	
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Figure 1. Expression and analysis of the HepcH chimeric construct.  380	
A: amino acid sequence of the HepcH monomer (camel hepcidin sequence in red; human 381	
ferritin H sequence in blue). B: SDS-PAGE analysis of the induced and non-induced E.coli 382	
transformed by the recombinant HepcH pASK-IBA 43 plus vector. Lane 1 and 2, induced and 383	
non-induced pellet respectively (insoluble fraction). Lane 3 and 4, induced and non-induced 384	
supernatant (soluble fraction). Lane 5 and 6, induced and non-induced total sonicate (total 385	
protein). C: Western blotting analysis of the denaturing PAGE of the recombinant HepcH 386	
monomer (2 different blots). Blot 1: lane 1, rabbit hepcidin antibodies recognized the 387	
commercial human hepcidin-25 (control). Lane 2, rabbit hepcidin antibodies recognized 388	
HepcH. Blot 2: lane 3, mouse rH02 antibodies recognized HepcH. Lane 4, mouse rH02 389	
antibodies recognized the recombinant human H-ferritin, huFTH, (control). D: MALDI-TOF 390	
mass analysis of the recombinant HepcH monomer. 391	
Figure 2. Iron is bound to the insoluble HepcH.  392	
A: The insoluble fraction of the E.coli expressing HepcH had a reddish color (left) distinct 393	
from the light brown color (at the right) of E. coli expressing huFTH. B: UV/Vis spectra of 394	
the two fractions solubilized in 5 M urea (0.5 mg/ml proteins) before and after incubation 395	
with 100 mM dithionite. C: UV-vis spectra of solubilized HepcH reduced with TCEP in the 396	
presence of ferrozine that readily chelates iron with the formation of the Fe(II)-ferrozine 397	
complex that absorbs at 562 nm. Inset: Absorbance at 562 nm plotted versus time shows the 398	
appearance of a plateau after 24 h of reaction. D: UV-vis spectra of HepcH monomer 399	
incubated with presence of ferrozine in absence of reducing agent. Inset: Absorbance at 562 400	
nm plotted versus time. 401	
Figure 3. Assembly of HepcH-FTH and -FTL heteropolymers.  402	
A: Non-denaturing PAGE analysis of the assembled HepcH-FTH obtained after mixing 403	
different ratios of denatured HepcH and FTH monomers. B: Non-denaturing PAGE analysis 404	
of the assembled heteropolymeric HepcH-FTH and HepcH-FTL at different ratios. C: Non-405	
denaturing PAGE analysis and Western blotting of the refolded HepcH-FTH and –FTL 406	
heteropolymers, using monoclonal anti-human FTH and FTL and polyclonal anti-hepcidin-25 407	
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antibodies, indicating that HepcH assembles in ferritin shells. Indeed, refolding of the HepcH 408	
alone was impossible due to hepcidin aggregates. D: Schematic representation of the possible 409	
geometries of the renatured HepcH-FT hybrid heteropolymer. Yellow star corresponds to the 410	
HepcH monomer. Ratio HepcH / FTH or FTL = 1:1, corresponding to average number of 12 411	
HepcH per 24 subunits. Ratio HepcH / FTH or FTL =1:2, corresponding to average number 412	
of 8 HepcH per 24 subunits. Ratio HepcH / FTH or FTL =1:5, corresponding to average 413	
number of 4 HepcH per 24 subunits. Ratio HepcH / FTH or FTL =1:11, corresponding to 414	
average number of 2 HepcH per 24 subunits. 415	
Figure 4. Characterization of cysteine oxidized heteropolymers.  416	
A: Non-denaturing PAGE analysis of the assembled heteropolymeric HepcH-FTH and 417	
HepcH-FTL heteropolymers after cysteine oxidation. Refolded native FTH and FTL were 418	
used as control. B Left: UV-vis spectra of Ellman’s assay of the final oxidized 419	
heteropolymeric HepcH-FTH (dashed) and HepcH-FTL (dots) at 1:5 ratios showing the 420	
absence of absorption bands at 412 nm. B Right: thiol quantification of HepcH-FTH (white 421	
column) and HepcH-FTL (black column) expressed as number of free sulfhydryl groups per 422	
HepcH moiety in the final heteropolymeric 24-mers, considering a number of 4 HepcH per 423	
shell. 424	
Figure 5. HepcH-FTH heteropolymers bind iron treated J774 cells and cause ferroportin 425	
degradation. A: Western blotting analysis of the non-denaturing PAGE of cell lysates after 426	
treatment with 0.2 µM HepcH-FTH (1:5 and 1:11) during 1 h and 2 h incubation using 427	
monoclonal anti-human FTH antibody. B: Western blotting analysis of the non-denaturing 428	
PAGE of cell lysates after treatment with 0.1 µM and 0.2 µM HepcH-FTL (1:5 and 1:11) 429	
during 1 h and 2 h incubation using monoclonal anti-human FTL antibody. Controls 430	
containing 0.2µM of native huFTH, and 0.1 µM and 0.2 µM of native huFTL were incubated 431	
at same final volumes and same reaction times with cells. NT, non-treated cells used as 432	
control. C: Western blotting analysis of the SDS-PAGE of cell lysates using polyclonal anti-433	
rabbit ferroportin antibody. CTR: untreated cells. FTH: cells treatment with 0.5 µM native 434	
FTH for 2 h. HepcH-FTH: cells treatment with 0.2 µM HepcH-FTH (1:5) for 2 h. Hepc: cells 435	
treatment with 0.5 µM synthetic human hepcidin-25 for 2 h. Non-adjacent bands, from the 436	






















      
HepcH	 213	 24,394.53	 24,410.50	 24,339.55*	 24,338.90	*	
24,230.14	*	
FTL	 175	 20,007.10	 20,019.67	 --	 20,055.41	*	










Table S1. Primers used in this study. 449	
Figure S1. Thiol quantification on the solubilized HepcH monomer.  450	
A: UV-vis spectra showing the results of Ellman’s assay for thiol detection in the solubilized 451	
HepcH monomer (dashed) and the HepcH monomer subjected to reductive treatment (black 452	
line). Spectra show the appearance of an absorption band at 412 nm after reductive treatment 453	
in HepcH revealing the presence of cysteine sulfhydryl-groups. B: Amount of free sulfhydryl-454	
groups per HepcH present in HepcH after reduction (black) and in the solubilized HepcH 455	
(white). 456	
Figure S2. MALDI-TOF spectra of the assembled HepcH-FTH (A) and -FTL (B) 457	
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A: Non-denaturing PAGE analysis of the assembled heteropolymeric HepcH-FTH and 507	
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Figure 5. HepcH-FTH heteropolymers bind iron treated J774 cells and cause ferroportin 518	
degradation. A: Western blotting analysis of the non-denaturing PAGE of cell lysates after 519	
treatment with 0.2 µM HepcH-FTH (1:5 and 1:11) during 1 h and 2 h incubation using 520	
monoclonal anti-human FTH antibody. B: Western blotting analysis of the non-denaturing 521	
PAGE of cell lysates after treatment with 0.1 µM and 0.2 µM HepcH-FTL (1:5 and 1:11) 522	
during 1 h and 2 h incubation using monoclonal anti-human FTL antibody. Controls 523	
containing 0.2µM of native huFTH, and 0.1 µM and 0.2 µM of native huFTL were incubated 524	
at same final volumes and same reaction times with cells. NT, non-treated cells used as 525	
control. C: Western blotting analysis of the SDS-PAGE of cell lysates using polyclonal anti-526	
rabbit ferroportin antibody. CTR: untreated cells. FTH: cells treatment with 0.5 µM native 527	
FTH for 2 h. HepcH-FTH: cells treatment with 0.2 µM HepcH-FTH (1:5) for 2 h. Hepc: cells 528	
treatment with 0.5 µM synthetic human hepcidin-25 for 2 h. Non-adjacent bands, from the 529	







Table S1. Primers used in this study.  535	
Primers 
 
Sequence 5’ to 3’ Using 
 







BamHI hFTH R 
 
TCGAGGGATCCCCGGGTTAGCTTTCATT huFTH construct 
NheI H25 F ATAGACGCTAGCATGGACACCCACTTCCCCATCTGC HepcH construct 
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A: UV-vis spectra showing the results of Ellman’s assay for thiol detection in the solubilized 542	
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Figure S2. MALDI-TOF spectra of the assembled HepcH-FTH (A) and -FTL (B) 550	
heteropolymers (ratio 1:5). 551	
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